JOHN L. HIGGINS - 15 Sep 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Executive Officer, Director
Signature: By: Charles S. Berkman For: John L. Higgins
Issuer symbol: LGND
Transactions as of: 15 Sep 2022
Transactions value $: -$448,050
Form type: 4
Filing time: 16 Sep 2022, 19:49:16 UTC
Previous filing: 12 Aug 2022
Next filing: 22 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Sale	-$180K	-2K	-0.54%	$90.00	367K	15 Sep 2022	Direct
transaction	LGND	Common Stock	Sale	-$268K	-3K	-0.82%	$89.35	364K	16 Sep 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $90.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $90.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.